» Articles » PMID: 21949093

The Pathophysiology of IgA Nephropathy

Overview
Specialty Nephrology
Date 2011 Sep 28
PMID 21949093
Citations 381
Authors
Affiliations
Soon will be listed here.
Abstract

Here we discuss recent advances in understanding the biochemical, immunologic, and genetic pathogenesis of IgA nephropathy, the most common primary glomerulonephritis. Current data indicate that at least four processes contribute to development of IgA nephropathy. Patients with IgA nephropathy often have a genetically determined increase in circulating levels of IgA1 with galactose-deficient O-glycans in the hinge-region (Hit 1). This glycosylation aberrancy is, however, not sufficient to induce renal injury. Synthesis and binding of antibodies directed against galactose-deficient IgA1 are required for formation of immune complexes that accumulate in the glomerular mesangium (Hits 2 and 3). These immune complexes activate mesangial cells, inducing proliferation and secretion of extracellular matrix, cytokines, and chemokines, which result in renal injury (Hit 4). Recent genome-wide association studies identify five distinct susceptibility loci--in the MHC on chromosome 6p21, the complement factor H locus on chromosome 1q32, and in a cluster of genes on chromosome 22q22--that potentially influence these processes and contain candidate mediators of disease. The significant variation in prevalence of risk alleles among different populations may also explain some of the sizable geographic variation in disease prevalence. Elucidation of the pathogenesis of IgA nephropathy provides an opportunity to develop disease-specific therapies.

Citing Articles

Targeted-release budesonide: A comprehensive review on its potential in IgA nephropathy.

Qi F, Zeng H, Zhang J Heliyon. 2025; 11(4):e42729.

PMID: 40061933 PMC: 11889547. DOI: 10.1016/j.heliyon.2025.e42729.


Expected and verified benefits from old and new corticosteroid treatments in IgA nephropathy: from trials in adults to new IPNA-KDIGO guidelines.

Peruzzi L, Coppo R Pediatr Nephrol. 2025; .

PMID: 40042624 DOI: 10.1007/s00467-025-06725-1.


Exploring the causal association between circulating leukocyte count and IgA nephropathy based on two-sample Mendelian randomization: possible role of transitional B cells.

Fang F, Wang H, Luo J, Hong F Clin Exp Nephrol. 2025; .

PMID: 40011364 DOI: 10.1007/s10157-025-02646-3.


Characteristics, pathogenic and therapeutic role of gut microbiota in immunoglobulin A nephropathy.

Yao K, Zheng L, Chen W, Xie Y, Liao C, Zhou T Front Immunol. 2025; 16:1438683.

PMID: 39981255 PMC: 11839611. DOI: 10.3389/fimmu.2025.1438683.


The road ahead: emerging therapies for primary IgA nephropathy.

Filippone E, Gulati R, Farber J Front Nephrol. 2025; 5:1545329.

PMID: 39968279 PMC: 11832374. DOI: 10.3389/fneph.2025.1545329.


References
1.
Leung J, Tsang A, Chan D, Lai K . Absence of CD89, polymeric immunoglobulin receptor, and asialoglycoprotein receptor on human mesangial cells. J Am Soc Nephrol. 2000; 11(2):241-249. DOI: 10.1681/ASN.V112241. View

2.
Varis J, Rantala I, Pasternack A, Oksa H, Jantti M, Paunu E . Immunoglobulin and complement deposition in glomeruli of 756 subjects who had committed suicide or met with a violent death. J Clin Pathol. 1993; 46(7):607-10. PMC: 501386. DOI: 10.1136/jcp.46.7.607. View

3.
Novak J, Tomana M, Matousovic K, Brown R, Hall S, Novak L . IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int. 2005; 67(2):504-13. DOI: 10.1111/j.1523-1755.2005.67107.x. View

4.
Imielinski M, Baldassano R, Griffiths A, Russell R, Annese V, Dubinsky M . Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet. 2009; 41(12):1335-40. PMC: 3267927. DOI: 10.1038/ng.489. View

5.
Lai K, Leung J, Chan L, Saleem M, Mathieson P, Lai F . Activation of podocytes by mesangial-derived TNF-alpha: glomerulo-podocytic communication in IgA nephropathy. Am J Physiol Renal Physiol. 2008; 294(4):F945-55. DOI: 10.1152/ajprenal.00423.2007. View